secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0000950170-23-017454
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stoke Therapeutics Q1 2023 net loss $0.53/sh; cash $254.2M; mid-2023 STK-001 data expected
--------------------------------------------------------------------------------

- Net loss per share $0.53, revenue $5.2M from collaboration (up from $3.0M YoY).
- Cash, equivalents and securities $254.2M, expected to fund operations to end of 2025.
- On track to report Phase 1/2a STK-001 data mid-2023: safety & seizure frequency for up to 16 patients on 45mg.
- UK MHRA authorized CTA for STK-002 Phase 1/2 study in ADOA; start expected early 2024.
- Company plans to initiate a Phase 3 program in 2024, pending additional Phase 1/2a data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000095017023017454/0000950170-23-017454-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000095017023017454/stok-20230504.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-017454

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer